Vasculitis Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vasculitis is a heterogeneous group of disorders characterised by inflammation of the blood vessel wall — arteries, veins, or capillaries — leading to vessel wall damage, stenosis, occlusion, or aneurysm formation. The inflammation disrupts the integrity of the vessel wall, causing ischaemia to the organs supplied by the affected vessels. Vasculitis can affect virtually any organ system, producing diverse clinical presentations ranging from skin purpura and haematuria to stroke, kidney failure, blindness, and bowel ischaemia depending on the calibre and distribution of vessels involved.

The classification of vasculitis is based on the vessel size predominantly affected, the underlying aetiology (primary autoimmune vs secondary to infection, drug reaction, or malignancy), and the histopathological pattern. The 2012 International Chapel Hill Consensus Conference (CHCC) Nomenclature provides the internationally accepted classification framework used by rheumatologists, nephrologists, and pulmonologists worldwide.

The pathogenesis varies by subtype. ANCA-associated vasculitides (AAV) — including granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) — are characterised by circulating anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA), which activate neutrophils and cause small vessel inflammation. Immune complex-mediated vasculitides (IgA vasculitis/Henoch-Schönlein purpura, cryoglobulinaemic vasculitis, anti-GBM disease) result from deposition of immune complexes in vessel walls triggering complement activation. Large vessel vasculitides (giant cell arteritis, Takayasu arteritis) are granulomatous inflammations of the aorta and its major branches mediated by T-helper 1 and T-helper 17 lymphocytes.

Treatment of vasculitis has been transformed by three decades of multicentre randomised trials, registry data, and the development of targeted biological therapies. The principal goals are remission induction (suppressing acute inflammation and preventing organ damage), maintenance of remission (preventing relapse), and minimisation of treatment toxicity — particularly the cumulative burden of corticosteroids and cytotoxic agents.

Vasculitis treatment is highly subtype-specific. The major vasculitic syndromes and their treatment implications include:

• Granulomatosis with polyangiitis (GPA / Wegener's granulomatosis): Small and medium vessel vasculitis associated with PR3-ANCA (85% of cases). Characterised by granulomatous inflammation of the upper and lower respiratory tract (nasal bridge destruction, sinusitis, subglottic stenosis, pulmonary nodules and cavities) and necrotising glomerulonephritis. Requires aggressive immunosuppression — rituximab is now the preferred induction agent over cyclophosphamide per RAVE trial evidence.
• Microscopic polyangiitis (MPA): Small vessel vasculitis associated with MPO-ANCA (80% of cases). Causes rapidly progressive glomerulonephritis and pulmonary haemorrhage (pulmonary-renal syndrome) without granulomas. High mortality if untreated; managed with rituximab or cyclophosphamide plus corticosteroids.
• Eosinophilic granulomatosis with polyangiitis (EGPA / Churg-Strauss syndrome): Associated with asthma, peripheral blood eosinophilia (>10%), and multi-organ involvement including mononeuritis multiplex, cardiac disease, skin purpura, and glomerulonephritis. MPO-ANCA positive in approximately 30–40%. Treated with corticosteroids; mepolizumab (anti-IL-5) is approved for relapsing-remitting EGPA.
• Giant cell arteritis (GCA / temporal arteritis): Large vessel granulomatous vasculitis affecting the aorta and its cranial branches, predominantly in patients aged >50 years. Risk of acute vision loss (anterior ischaemic optic neuropathy) and stroke. High-dose corticosteroids are the cornerstone; tocilizumab (IL-6 receptor antagonist) is now approved as a corticosteroid-sparing agent (GiACTA trial).
• Takayasu arteritis: Granulomatous large vessel vasculitis affecting the aorta and its primary branches in predominantly young women aged 10–40 years. Causes limb claudication, hypertension, aortic regurgitation, and stroke. Treated with high-dose corticosteroids; methotrexate, azathioprine, or biologics (tocilizumab, infliximab) for maintenance.
• Polyarteritis nodosa (PAN): Medium vessel vasculitis (non-ANCA associated) causing infarction of kidneys, bowel, peripheral nerves, and skin. Strongly associated with hepatitis B virus in endemic regions. ANCA-negative. Corticosteroids with cyclophosphamide for severe cases; antiviral therapy for HBV-associated PAN.
• IgA vasculitis (Henoch-Schönlein purpura): Most common vasculitis in children; also occurs in adults. IgA immune complex deposition in small vessels causes purpura (buttocks/legs), arthritis, abdominal pain, and IgA nephropathy. Generally self-limiting in children; adults with renal involvement may require corticosteroids and RAAS blockade.
• Kawasaki disease: Medium vessel vasculitis of infancy and early childhood causing prolonged fever, mucocutaneous inflammation, and coronary artery aneurysms in 15–25% of untreated cases. High-dose IVIG plus aspirin is standard treatment, reducing coronary aneurysm risk to <5%.

Treatment decisions in vasculitis depend on the diagnosis, disease severity, organ involvement, and individual patient factors:

• Confirmed diagnosis: Treatment with immunosuppression should only be initiated after a confident diagnosis — established through clinical assessment, ANCA serology, biopsy (renal, skin, temporal artery, lung), and imaging (CT chest/abdomen, PET-CT for large vessel vasculitis). Tissue biopsy remains the gold standard for most subtypes. Empirical treatment without diagnosis risks exposing patients to immunosuppressive toxicity for non-vasculitic conditions.
• Organ-threatening or life-threatening disease: Active ANCA vasculitis causing rapidly progressive glomerulonephritis (rising creatinine, active urine sediment with red cell casts), alveolar haemorrhage, mononeuritis multiplex, or intestinal ischaemia requires urgent induction immunosuppression — treatment should not be delayed. Elevated serum creatinine >500 micromol/L at presentation significantly worsens long-term renal prognosis.
• Relapsing disease: Up to 50% of GPA patients and 30% of MPA patients relapse within 5 years of achieving remission. Relapse — defined as recurrence of disease activity in a previously quiescent patient — requires re-induction therapy. Rising PR3-ANCA titres (in PR3-ANCA positive GPA) predict relapse and may prompt pre-emptive therapy escalation.
• Large vessel vasculitis: GCA requires immediate high-dose corticosteroids upon clinical suspicion (before biopsy results) given the risk of irreversible blindness. Temporal artery biopsy should be obtained within 1–2 weeks of starting corticosteroids without delaying treatment. Tocilizumab is added for patients with relapsing GCA or at high risk of corticosteroid complications.
• Vasculitis severity assessment tools: The Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI) are validated tools used in clinical trials and specialist practice to quantify disease activity and cumulative organ damage, guiding treatment intensity decisions.

Treatment of vasculitis follows a two-phase strategy: induction of remission (aggressive immunosuppression to control active inflammation) followed by maintenance of remission (gentler long-term immunosuppression to prevent relapse and minimise toxicity):

1. Corticosteroids (glucocorticoids): The universal backbone of vasculitis treatment across all subtypes. High-dose prednisolone (1 mg/kg/day, typically 60–80 mg/day) is used for induction, with IV methylprednisolone pulses (500–1,000 mg IV for 3 days) for the most severe presentations (pulmonary haemorrhage, rapidly progressive GN). Dose is tapered over 12–18 months to the minimum effective dose. Prolonged corticosteroid use drives significant cumulative toxicity (see Risks section), prompting development of steroid-sparing strategies.
2. Rituximab (anti-CD20 monoclonal antibody): B-cell depleting therapy that has become the preferred induction agent over cyclophosphamide for GPA and MPA in most patients. The RAVE trial (NEJM, 2010) demonstrated non-inferiority of rituximab versus cyclophosphamide for remission induction in AAV, with superiority in relapsing disease. Standard induction: rituximab 375 mg/m² IV weekly for 4 doses, or 1,000 mg IV in 2 doses 2 weeks apart. Maintenance rituximab (500–1,000 mg every 6 months for 24 months) reduces relapse risk compared to azathioprine.
3. Cyclophosphamide (oral or IV pulse): An alkylating agent historically the standard of care for severe ANCA vasculitis induction. IV pulse cyclophosphamide (15 mg/kg every 2–3 weeks for 6 pulses) is preferred over oral daily dosing for equivalent efficacy with lower cumulative dose and fewer adverse effects (CYCLOPS trial). Now primarily used when rituximab is unavailable, contraindicated (hypogammaglobulinaemia, prior rituximab failure), or in combination for the most severe presentations.
4. Tocilizumab (IL-6 receptor antagonist): Approved for GCA based on the GiACTA trial (NEJM, 2017), which demonstrated that weekly or fortnightly subcutaneous tocilizumab significantly increased sustained remission rates and reduced the cumulative corticosteroid dose compared to placebo. Given subcutaneously (162 mg weekly or every 2 weeks) or IV. Also increasingly used off-label for Takayasu arteritis refractory to conventional immunosuppression.
5. Mepolizumab (anti-IL-5 monoclonal antibody): FDA-approved for EGPA based on the MIRRA trial (NEJM, 2017), demonstrating significantly increased remission duration and reduced relapse rates versus placebo in patients with relapsing or refractory EGPA. Given as 300 mg subcutaneous injection monthly. Particularly effective for eosinophil-driven manifestations (asthma, skin, sinus disease) while less effective for neuropathy.
6. Avacopan (C5a receptor antagonist, Tavneos): A novel oral complement inhibitor targeting the C5a receptor on neutrophils, approved in 2021 based on the ADVOCATE trial (NEJM, 2021) which demonstrated superiority to prednisolone taper at week 52 in achieving and maintaining remission in ANCA vasculitis, with a significantly lower cumulative steroid burden. Represents a significant advancement in corticosteroid-sparing strategies.
7. Maintenance immunosuppressants: After remission induction with rituximab or cyclophosphamide, maintenance therapy reduces relapse risk. Options include: azathioprine (2 mg/kg/day orally) — most widely used maintenance agent; mycophenolate mofetil (MMF) (2–3 g/day) — an alternative with similar efficacy to azathioprine in MPA; methotrexate (20–25 mg/week oral or SC) — for GPA patients with predominantly upper respiratory disease and preserved renal function. Rituximab maintenance (fixed dosing or ANCA-guided re-dosing) is now preferred for GPA by many centres.
8. Plasma exchange (PLEX/plasmapheresis): Historically used in severe ANCA vasculitis with dialysis-dependent renal failure or severe alveolar haemorrhage. The large PEXIVAS trial (NEJM, 2020) demonstrated that PLEX did not reduce the risk of end-stage kidney disease or death versus standard of care, and reduced serious infections. PLEX is now no longer routinely recommended for ANCA vasculitis, though it remains the cornerstone of treatment for anti-GBM disease (Goodpasture syndrome).

Effective immunosuppressive treatment of vasculitis produces dramatic improvements in survival and organ function:

• Remission induction: With modern immunosuppressive protocols, complete remission is achieved in 80–90% of ANCA-associated vasculitis patients within 3–6 months. Before effective immunosuppression was available, untreated GPA had a median survival of less than 5 months. Current 5-year survival rates exceed 80–85% in most specialised centres.
• Organ preservation: Early aggressive treatment prevents irreversible organ damage. In GCA, immediate high-dose corticosteroids prevent ischaemic optic neuropathy and blindness in the vast majority of patients who receive prompt treatment. In ANCA vasculitis, early treatment can prevent progression to dialysis-dependent kidney failure — patients who avoid dialysis at 3 months have significantly better long-term renal outcomes.
• Rituximab superiority in relapsing disease: The RAVE trial demonstrated complete remission with no prednisone at month 6 in 67% of rituximab-treated patients versus 42% of cyclophosphamide-treated patients in the relapsing disease subgroup, establishing rituximab as the preferred agent for relapse induction.
• Corticosteroid-sparing with biologics: Tocilizumab in GCA and avacopan in ANCA vasculitis significantly reduce the cumulative steroid dose required to maintain remission, directly reducing corticosteroid-associated morbidity including diabetes, osteoporosis, cataracts, hypertension, and serious infections.
• Prevention of vascular complications: In large vessel vasculitis (GCA, Takayasu), effective treatment prevents progression to aortic aneurysm, aortic regurgitation, stroke, and limb ischaemia — complications that carry significant mortality and disability.
• Quality of life restoration: The BVAS-WG, SF-36, and PROMIS instruments consistently demonstrate significant improvements in physical function, fatigue, and health-related quality of life following successful remission induction, comparable to gains achieved by treatment of other major chronic diseases.

Vasculitis treatment carries significant immunosuppression-related risks that must be carefully monitored and mitigated:

• Serious infections: The most common and most dangerous treatment complication. Risk is highest during induction with cyclophosphamide plus high-dose corticosteroids. Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection preventable with co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis — recommended for all patients on cyclophosphamide or rituximab plus corticosteroids. CMV reactivation and bacterial sepsis are also significant risks. Vaccination review (influenza, pneumococcal, COVID-19) is essential before starting immunosuppression; live vaccines are contraindicated during therapy.
• Corticosteroid toxicity: Cumulative steroid exposure causes new-onset diabetes mellitus (25–30% of patients), osteoporosis and vertebral fractures (requiring calcium, vitamin D, and bisphosphonate prophylaxis), hypertension, cataract, adrenal suppression, weight gain, mood disturbance, and impaired wound healing. The average cumulative prednisolone dose in ANCA vasculitis trials is 10–20 g over 12 months — highlighting the importance of corticosteroid-sparing strategies.
• Cyclophosphamide toxicity: Haemorrhagic cystitis (urothelial toxicity from acrolein metabolite) is prevented with adequate hydration, morning dosing, and mesna co-administration for IV pulses. Bladder cancer risk is increased with cumulative cyclophosphamide doses >36 g. Gonadal toxicity causing premature ovarian failure and male infertility must be discussed; fertility preservation before treatment should be offered to all reproductive-age patients. Bone marrow suppression (neutropenia) requires regular FBC monitoring.
• Rituximab-associated risks: Infusion reactions (managed with pre-medication) occur in 10–15%. Progressive multifocal leukoencephalopathy (PML, caused by JC virus reactivation) is a rare but catastrophic complication (<0.1%). Hypogammaglobulinaemia (low IgG levels from B-cell depletion) increases infection susceptibility over time and may require IVIG replacement. Rituximab does not impair fertility and is preferred in reproductive-age patients.
• Malignancy risk: Long-term immunosuppression — particularly cyclophosphamide — increases risk of bladder cancer (6-fold), haematological malignancies, and potentially solid organ cancers. Regular urinalysis and cystoscopy surveillance are recommended for patients with significant cumulative cyclophosphamide exposure. Skin protection from UV light reduces non-melanoma skin cancer risk.
• Disease relapse: Despite optimal treatment, vasculitis relapses in 30–50% of ANCA vasculitis patients within 5 years. Relapses may occur in the same or different organ systems as initial disease. PR3-ANCA positive GPA has substantially higher relapse rates than MPO-ANCA MPA. Regular clinical review and ANCA monitoring enable early relapse detection.
• Cumulative organ damage: The Vasculitis Damage Index (VDI) quantifies irreversible damage attributable to disease, treatment, or both. Renal impairment (from GN), hearing loss (from sinus/middle ear involvement in GPA), subglottic stenosis, neuropathy, and corticosteroid-induced osteoporosis are the most common long-term damage items recorded.

Vasculitis is a chronic relapsing condition requiring lifelong specialist follow-up to monitor disease activity, medication toxicity, and organ function:

• ANCA monitoring: PR3-ANCA and MPO-ANCA titres are measured every 3 months during the first year, then every 6 months in stable remission. Rising PR3-ANCA titres in GPA predict relapse risk with a positive predictive value of approximately 60–80% and may prompt pre-emptive rituximab redosing before clinical relapse occurs. MPO-ANCA titre changes are less predictive of relapse in MPA and EGPA.
• Renal function monitoring: Urinalysis (for haematuria, proteinuria indicating active nephritis), serum creatinine/eGFR, and urine albumin:creatinine ratio (ACR) are assessed at every clinic visit. Patients who recovered renal function require long-term nephrology follow-up and RAAS blockade (ACE inhibitor or ARB) to slow progression of CKD from residual renal scarring.
• Corticosteroid toxicity screening: Annual DEXA scan for bone density; ophthalmological review for steroid cataract; blood pressure and fasting glucose monitoring at every visit; adrenal function testing before stopping steroids after prolonged courses. Calcium 1,000–1,500 mg/day and vitamin D 800–1,000 IU/day supplementation, plus bisphosphonate therapy for patients receiving >7.5 mg prednisolone for >3 months, are recommended per ACR/EULAR guidelines.
• Infection screening: Regular FBC to detect cyclophosphamide-induced neutropenia; IgG levels every 6–12 months in patients on rituximab maintenance. Annual tuberculosis screening (IGRA or tuberculin test) before initiating or continuing biologic therapy. Hepatitis B serology and vaccination before rituximab or cyclophosphamide. PJP prophylaxis throughout cyclophosphamide therapy and for 6 months after rituximab.
• Pulmonary monitoring: Lung function tests (spirometry, DLCO) every 12 months in patients with pulmonary involvement. CT chest if new respiratory symptoms develop. Subglottic stenosis monitoring in GPA patients with history of tracheal involvement — laryngoscopy if stridor or voice changes occur.
• Cardiovascular risk management: Vasculitis patients — particularly those with GCA — have significantly increased cardiovascular risk from systemic inflammation and corticosteroid-induced dyslipidaemia, hypertension, and insulin resistance. Statin therapy, blood pressure control, and smoking cessation are important adjuncts to disease-specific treatment.
• Patient-reported outcomes: Fatigue is the most common patient-reported concern in vasculitis regardless of BVAS score. Structured assessment of fatigue, sleep, and psychological wellbeing using PROMIS-Fatigue and PHQ-9 instruments identifies patients who may benefit from occupational therapy, cognitive behavioural therapy, or graded exercise programmes.

The economic burden of vasculitis is substantial, driven by the complexity of diagnostic workup, the high cost of biologic agents, hospitalisation for acute disease, and long-term specialist care:

• Biologic agent costs: Rituximab for induction and maintenance is the largest single treatment cost driver. The annual cost of rituximab maintenance (500 mg IV every 6 months) is approximately USD 20,000–40,000 in the USA. Tocilizumab (GCA) costs USD 15,000–25,000 per year; mepolizumab (EGPA) USD 30,000–50,000; avacopan (AAV) USD 100,000+ per year. Biosimilar rituximab (available in Europe, India, and Asia) costs 30–60% less than the originator. Biosimilar adoption significantly improves access in resource-limited settings.
• Hospitalisation for acute vasculitis: Severe presentations requiring IV methylprednisolone pulses, IV cyclophosphamide, intensive care, or haemodialysis generate significant hospitalisation costs. ICU management for alveolar haemorrhage in pulmonary-renal syndrome can cost USD 10,000–30,000 per admission in high-income countries.
• Diagnostic workup: Temporal artery biopsy, renal biopsy, bronchoscopy, CT-PET imaging, ANCA serology, renal function monitoring, bone density scanning, and regular blood tests contribute significant cumulative diagnostic costs over the disease course.
• Dialysis and transplantation: Patients who progress to end-stage renal disease (ESRD) — approximately 20–25% of ANCA vasculitis patients at 5 years — require long-term haemodialysis or peritoneal dialysis (annual cost USD 70,000–90,000 in the USA) or renal transplantation. Vasculitis does not significantly affect kidney transplant outcomes if disease is in remission at time of transplantation.
• Access by geography: In the UK (NHS), rituximab for ANCA vasculitis and tocilizumab for GCA are approved and funded. In many low- and middle-income countries, access to biologics is limited to patients who can self-fund or access through clinical trials. Generic azathioprine, methotrexate, and prednisolone remain affordable globally. Medical tourism to India and Turkey enables access to biosimilar rituximab at substantially lower costs for international patients.

While immunosuppression is mandatory for organ-threatening vasculitis, several alternative and emerging approaches are expanding treatment options and reducing toxicity:

• Plasma exchange (PLEX) — selected indications: Despite the PEXIVAS trial results showing no benefit in ANCA vasculitis, plasma exchange remains the cornerstone of treatment for anti-GBM disease (Goodpasture syndrome) — a non-ANCA vasculitis mediated by antibodies against glomerular and alveolar basement membrane — and may have a role in cryoglobulinaemic vasculitis with severe hyperviscosity.
• Belimumab (anti-BLYS) and other emerging B-cell targeted agents: Belimumab is under investigation for maintenance of remission in ANCA vasculitis. Obinutuzumab (anti-CD20, type II) and daratumumab (anti-CD38, targeting plasma cells) are being explored for refractory rituximab-resistant AAV in early-phase trials.
• Abatacept (CTLA4-Ig, T-cell co-stimulation blockade): Evaluated in GPA as a maintenance therapy in the ABROGATE trial. Early results suggest benefit in reducing relapse rates for non-severe GPA, potentially offering a non-depleting alternative to rituximab for maintenance.
• Surgical and interventional vascular approaches: In large vessel vasculitis (Takayasu arteritis, GCA) with haemodynamically significant stenoses or aneurysms, surgical bypass grafting or endovascular angioplasty and stenting can restore perfusion to ischaemic territories. Ideally performed during disease remission to minimise re-stenosis rates. Coronary artery involvement in Kawasaki disease may require angioplasty or coronary artery bypass grafting in severe cases.
• Supportive care: For patients with end-stage organ damage (ESRD, advanced lung fibrosis, severe neuropathy) in whom further immunosuppression carries unacceptable risk, supportive care — including renal replacement therapy, pain management, physiotherapy, and palliative care — addresses symptoms and improves quality of life without systemic immunosuppression.
• Patient education and self-management: Structured patient education programmes covering disease recognition, medication adherence, early warning signs of relapse, and infection prevention are associated with improved outcomes and reduced emergency admissions. Vasculitis UK, Vasculitis Foundation, and similar patient organisations provide valuable peer support and educational resources.